Intest Res.  2018 Jul;16(3):494-498. 10.5217/ir.2018.16.3.494.

Effect of elemental diet combined with infliximab dose escalation in patients with Crohn's disease with loss of response to infliximab: CERISIER trial

• Hisamatsu
• Kunisaki R
• Nakamura S
• Tsujikawa
• Hirai F
• Nakase H
• Watanabe K
• Yokoyama K
• Nagahori M
• Kanai T
• Naganuma M
• Michimae H
• Andoh A
• Yamada A
• Yokoyama T
• Kamata N
• Tanaka S
• Suzuki Y
• Hibi T
• Watanabe M
• CERISIER Trial group

• KMID: 2417663
• DOI: http://doi.org/10.5217/ir.2018.16.3.494

Abstract

No abstract available.

MeSH Terms

Crohn Disease*
Food, Formulated*
Humans
Infliximab*
Infliximab

Figure

• 

  Fig. 1 Percentage of patients with a decrease in CDAI from weeks 8 to 56. (A) The percentage of patients who satisfied the ΔCDAI of ≥50 from weeks 8 to 56 of treatment is shown. Proportions of patients were compared between the groups by Fisher's exact test. Statistical analyses were performed at a two-sided significance level of 0.05. (B) The percentage of patients who achieved clinical remission, as indicated by a CDAI of <150, from weeks 8 to 56 of treatment is shown. Proportions of patients were compared between the groups by Fisher's exact test. Statistical analyses were performed at a two-sided significance level of 0.05. aSignificant difference. ED, elemental diet; IFX, infliximab.

• 

  Fig. 2 Cumulative rate of successful completion of the scheduled maintenance treatment with IFX infusion at 10 mg/kg every 8 weeks until week 56. (A) The scheduled maintenance treatment continuation rate curve was estimated by the Kaplan-Meier method for each group, and the groups were compared by the generalized Wilcoxon test (per-protocol set). (B) The scheduled maintenance treatment continuation rate curve was estimated by the Kaplan-Meier method for each group, and the groups were compared by the generalized Wilcoxon test (full analysis set). IFX, infliximab; ED, elemental diet.

Reference

1. Chan HC, Ng SC. Emerging biologics in inflammatory bowel disease. J Gastroenterol. 2017; 52:141–150. PMID: 27832357.

2. Akobeng AK, Thomas AG. Enteral nutrition for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2007; (3):CD005984. DOI: 10.1002/14651858.CD005984.pub2. PMID: 17636816.

3. Yamamoto T, Nakahigashi M, Umegae S, Matsumoto K. Enteral nutrition for the maintenance of remission in Crohn's disease: a systematic review. Eur J Gastroenterol Hepatol. 2010; 22:1–8. PMID: 19707151.

4. Tsertsvadze A, Gurung T, Court R, Clarke A, Sutcliffe P. Clinical effectiveness and cost-effectiveness of elemental nutrition for the maintenance of remission in Crohn's disease: a systematic review and meta-analysis. Health Technol Assess. 2015; 19:1–138.

5. Hirai F, Ishihara H, Yada S, et al. Effectiveness of concomitant enteral nutrition therapy and infliximab for maintenance treatment of Crohn's disease in adults. Dig Dis Sci. 2013; 58:1329–1334. PMID: 22926500.

6. Kamata N, Oshitani N, Watanabe K, et al. Efficacy of concomitant elemental diet therapy in scheduled infliximab therapy in patients with Crohn's disease to prevent loss of response. Dig Dis Sci. 2015; 60:1382–1388. PMID: 25532505.

7. Sazuka S, Katsuno T, Nakagawa T, et al. Concomitant use of enteral nutrition therapy is associated with sustained response to infliximab in patients with Crohn's disease. Eur J Clin Nutr. 2012; 66:1219–1223. PMID: 23010687.

8. Sugita N, Watanabe K, Kamata N, et al. Efficacy of a concomitant elemental diet to reduce the loss of response to adalimumab in patients with intractable Crohn's disease. J Gastroenterol Hepatol. 2018; 33:631–637. PMID: 28857255.

9. Nguyen DL, Palmer LB, Nguyen ET, McClave SA, Martindale RG, Bechtold ML. Specialized enteral nutrition therapy in Crohn's disease patients on maintenance infliximab therapy: a meta-analysis. Therap Adv Gastroenterol. 2015; 8:168–175.

10. Yamamoto T, Nakahigashi M, Umegae S, Matsumoto K. Prospective clinical trial: enteral nutrition during maintenance infliximab in Crohn's disease. J Gastroenterol. 2010; 45:24–29. PMID: 19798465.